Targeted Cancer Therapies: Quiz Yourself on the Latest Advancements

Question 1

Which attribute is NOT characteristic of targeted therapies?

Accepted Answer

Broad-spectrum activity against various targets

Answer

High target specificity and selectivity

Answer

Capacity to inhibit specific molecular targets

Answer

Enhanced effectiveness against resistant cancers

Question 2

Tyrosine kinase inhibitors predominantly target:

Accepted Answer

Intracellular signaling pathways

Answer

Cell surface receptors

Answer

DNA repair pathways

Answer

Microtubule function

Question 3

Which of these is an example of a monoclonal antibody employed in cancer therapy?

Accepted Answer

Trastuzumab

Answer

Imatinib

Answer

Olaparib

Answer

Pazopanib

Question 4

PARP inhibitors are primarily effective in treating cancers with which genetic defect?

Accepted Answer

BRCA1/BRCA2 mutations

Answer

EGFR overexpression

Answer

HER2 amplification

Answer

KRAS mutations

Question 5

Monoclonal antibodies are commonly used to target which component of cancer cells?

Accepted Answer

Surface antigens

Answer

Enzymes

Answer

DNA

Answer

RNA

Question 6

Which tyrosine kinase inhibitor is commonly employed in chronic myeloid leukemia treatment?

Accepted Answer

Imatinib

Answer

Erlotinib

Answer

Gefitinib

Answer

Sorafenib

Question 7

Which monoclonal antibody targets the epidermal growth factor receptor (EGFR)?

Accepted Answer

Cetuximab

Answer

Bevacizumab

Answer

Trastuzumab

Answer

Rituximab

Question 8

Which of the following is a PARP inhibitor mechanism of action?

Accepted Answer

DNA repair inhibition

Answer

Apoptosis induction

Answer

Angiogenesis stimulation

Answer

Cell cycle progression blockade

Question 9

Which of the following mechanisms does NOT contribute to the action of tyrosine kinase inhibitors?

Accepted Answer

Activation of the patient's immune system

Answer

Inhibition of intracellular signal transduction

Answer

Induction of programmed cell death (apoptosis)

Answer

Interference with cell cycle progression

Question 10

Which monoclonal antibody is used to treat patients with HER2-positive breast cancer?

Accepted Answer

Trastuzumab

Answer

Bevacizumab

Answer

Cetuximab

Answer

Rituximab

Question 11

Which of the following is a distinguishing feature of targeted therapies compared to traditional cytotoxic chemotherapy?

Accepted Answer

Higher efficacy and lower toxicity

Answer

Lower efficacy and higher toxicity

Answer

Equal efficacy and toxicity

Answer

Higher efficacy and higher toxicity

Question 12

Which of the following is NOT a type of targeted therapy?

Accepted Answer

Immunotherapy

Answer

Tyrosine kinase inhibitors

Answer

Monoclonal antibodies

Answer

PARP inhibitors

Question 13

What is the specific molecular target of the PARP inhibitor olaparib?

Accepted Answer

PARP

Answer

VEGF

Answer

HER2

Answer

PD-1

Question 14

What is the primary objective of pharmacodynamic monitoring in targeted therapy?

Accepted Answer

To detect early signs of drug resistance

Answer

To optimize drug dosing

Answer

To prevent adverse drug reactions

Answer

To assess adherence to treatment

Question 15

Which of the following mechanisms of action is NOT characteristic of targeted therapies?

Accepted Answer

Stimulating angiogenesis

Answer

Inhibiting cell cycle progression

Answer

Inducing apoptosis

Answer

Blocking growth factor signaling pathways

Question 16

Trastuzumab, a monoclonal antibody, selectively targets which cell surface receptor in cancer cells?

Accepted Answer

HER2

Answer

EGFR

Answer

VEGFR

Answer

PD-1

Question 17

Imatinib, a tyrosine kinase inhibitor, is primarily used in the treatment of which type of cancer?

Accepted Answer

Chronic myeloid leukemia

Answer

Non-small cell lung cancer

Answer

Breast cancer

Answer

Colorectal cancer

Question 18

Tyrosine kinase inhibitors (TKIs) target which of the following molecular entities?

Accepted Answer

Receptor tyrosine kinases

Answer

G-protein coupled receptors

Answer

Ion channels

Answer

Nuclear receptors

Question 19

What is the primary mechanism of action for monoclonal antibodies (mAbs) in targeted therapy?

Accepted Answer

Binding to specific antigens on cells or molecules

Answer

Inhibiting DNA synthesis

Answer

Activating immune cells

Answer

Interfering with cell cycle progression

Question 20

A common adverse effect associated with PARP inhibitors is:

Accepted Answer

Myelosuppression

Answer

Cardiotoxicity

Answer

Nausea

Answer

Hepatotoxicity

Question 21

What is the primary role of the HER2 protein in cancer cell growth and survival?

Accepted Answer

Promotes cell proliferation and survival

Answer

Stimulates angiogenesis

Answer

Inhibits cell death

Question 22

Which of the following is a defining characteristic of targeted therapies in cancer treatment?

Accepted Answer

High specificity for cancer cells

Answer

Low toxicity

Answer

Requirement for high doses

Answer

Broad spectrum of activity

Question 23

Compared to traditional chemotherapy, a potential advantage of using targeted therapies is:

Accepted Answer

Reduced side effects due to specific targeting

Answer

Faster onset of action

Answer

Higher cure rates

Question 24

A crucial factor in selecting the most appropriate targeted therapy for an individual patient is:

Accepted Answer

Genetic profiling of tumor tissue

Answer

Patient preference

Answer

Patient age

Answer

Stage of disease

Question 25

Artificial intelligence (AI) is increasingly playing a role in targeted therapy development. What is one of its potential applications?

Accepted Answer

Identification of new drug targets

Answer

Dosage calculation

Answer

Administration of treatments

Answer

Patient monitoring

Question 26

A key ethical concern surrounding the use of targeted therapies is:

Accepted Answer

Equity of access to expensive therapies

Answer

Informed consent

Answer

Data privacy

Answer

Environmental impact